RETRACTED: CircASXL1 Knockdown Restrains Hypoxia-Induced DDP Resistance and NSCLC Progression by Sponging miR-206 (Retracted article. See vol. 14, pg. 2203, 2022)

被引:21
作者
Yu, Liuyang [1 ]
Li, Jing [2 ]
Peng, Bing [1 ]
Cai, Peng [1 ]
Zhao, Bailin [1 ]
Chen, Ying [3 ]
Zhu, Hailing [4 ]
机构
[1] Jing Men 2 Peoples Hosp, Dept Oncol, Jingmen 448000, Hubei, Peoples R China
[2] Jing Men 2 Peoples Hosp, Dept Imaging, Jingmen 448000, Hubei, Peoples R China
[3] Jing Men 2 Peoples Hosp, Dept Radiotherapy, Jingmen 448000, Hubei, Peoples R China
[4] Jing Men 1 Peoples Hosp, Dept Emergency, 168 Xiangshan Dadao, Jingmen 448000, Hubei, Peoples R China
关键词
hypoxia; circASXL1; miR-206; DDP; NSCLC; CELL LUNG-CANCER; CISPLATIN RESISTANCE; EXPRESSION; PROMOTES; CHEMORESISTANCE; METASTASIS; STATISTICS; CARCINOMA; INVASION; BREAST;
D O I
10.2147/CMAR.S276964
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Non-small cell lung carcinoma (NSCLC) is a primary prevalent type of cancer in people worldwide. Cisplatin (DDP) has been widely used to treat NSCLC; however, its curative effect was restrained under hypoxia. In this study, the effects of hypoxia treatment on DDP resistance and NSCLC progression and underneath mechanism were revealed. Methods: The expression of circular RNA ASXL1 (circASXL1) and microRNA-206 (miR-206) in NSCLC tissues, cells and hypoxia-mediated NSCLC cells was determined by quantitative real-time polymerase chain reaction (qRT-PCR). The expression of proliferation, metastasis and apoptosis-related proteins, drug resistance-related protein and hypoxia-inducible factor-1alpha (HIF-1 alpha) protein was detected by Western blot. The effects of circASXL1 knockdown on hypoxia-induced DDP resistance and NSCLC progression were revealed by cell counting kit-8 proliferation (CCK-8), cell colony formation, transwell and flow apoptosis assays. RNA immunoprecipitation (RIP) assay was performed to determine whether circASXL1 could form silence-inducing complexes with miRNA. The associated relationship between circASXL1 and miR-206 was predicted by circBank online database, and identified by RNA pull-down and dual-luciferase reporter assays. The effects between circASXL1 knockdown and miR-206 downregulation on tumor growth in vivo were investigated by in vivo tumor formation assay. Results: CircASXL1 expression was dramatically upregulated, whereas miR-206 was significantly down-regulated in NSCLC tissues, cells and hypoxia-mediated NSCLC cells as compared to control groups. CircASXL1 knockdown reversed hypoxia-mediated promotion effects on DDP resistance, cell proliferation, migration, and invasion, and inhibition impact on cell apoptosis, whereas these effects were restored by miR-206 inhibitor. Additionally, circASXL1 was found to form silence-inducing complexes with miRNA and act as a sponge of miR-206. CircASXL1 silencing downregulated HIF-1 alpha expression by controlling miR-206 expression. Furthermore, circASXL1 silencing repressed tumor growth in vivo by sponging miR-206. Conclusion: CircASXL1 knockdown inhibited DDP resistance, cell proliferation, migration and invasion, whereas induced cell apoptosis under hypoxia by associating with miR-206 in NSCLC. This study provides a new sight in treating NSCLC with DDP under hypoxia.
引用
收藏
页码:5077 / 5089
页数:13
相关论文
共 33 条
[1]   Glycine decarboxylase and HIF-1α expression are negative prognostic factors in primary resected early-stage non-small cell lung cancer [J].
Berezowska, Sabina ;
Galvan, Jose A. ;
Langer, Rupert ;
Bubendorf, Lukas ;
Savic, Spasenija ;
Gugger, Mathias ;
Schmid, Ralph A. ;
Marti, Thomas M. .
VIRCHOWS ARCHIV, 2017, 470 (03) :323-330
[2]   miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET [J].
Chen, Qing-yong ;
Jiao, De-min ;
Wang, Jian ;
Hu, Huizhen ;
Tang, Xiali ;
Chen, Jun ;
Mou, Hao ;
Lu, Wei .
ONCOTARGET, 2016, 7 (17) :24510-24526
[3]   Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1 [J].
Chou, Chii-Wen ;
Wang, Chi-Chung ;
Wu, Chung-Pu ;
Lin, Yu-Jung ;
Lee, Yu-Chun ;
Cheng, Ya-Wen ;
Hsieh, Chia-Hung .
NEURO-ONCOLOGY, 2012, 14 (10) :1227-1238
[4]   Circular RNAs: Identification, biogenesis and function [J].
Ebbesen, Karoline K. ;
Kjems, Jorgen ;
Hansen, Thomas B. .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2016, 1859 (01) :163-168
[5]   Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization [J].
Fischer, Carina ;
Leithner, Katharina ;
Wohlkoenig, Christoph ;
Quehenberger, Franz ;
Bertsch, Alexandra ;
Olschewski, Andrea ;
Olschewski, Horst ;
Hrzenjak, Andelko .
MOLECULAR CANCER, 2015, 14
[6]   TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells [J].
Flamant, Lionel ;
Roegiers, Edith ;
Pierre, Michael ;
Hayez, Aurelie ;
Sterpin, Christiane ;
De Backer, Olivier ;
Arnould, Thierry ;
Poumay, Yves ;
Michiels, Carine .
BMC CANCER, 2012, 12
[7]   miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2 [J].
Gao, Peng ;
Wang, Huan ;
Yu, Jiarui ;
Zhang, Jie ;
Yang, Zhao ;
Liu, Meiyue ;
Niu, Yi ;
Wei, Xiaomei ;
Wang, Wei ;
Li, Hongmin ;
Wang, Yadi ;
Sun, Guogui .
PLOS GENETICS, 2018, 14 (12)
[8]   Regulation of microRNA function in animals [J].
Gebert, Luca F. R. ;
MacRae, Ian J. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2019, 20 (01) :21-37
[9]   RETRACTED: The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells (Retracted article. See vol. 63, 2021) [J].
Guo, Jiwei ;
Jin, Dan ;
Wu, Yan ;
Yang, Lijuan ;
Du, Jing ;
Gong, Kaikai ;
Chen, Weiwei ;
Dai, Juanjuan ;
Miao, Shuang ;
Xi, Sichuan .
EBIOMEDICINE, 2018, 35 :204-221
[10]   HIF-1α Promotes the Metastasis of Esophageal Squamous Cell Carcinoma by Targeting SP1 [J].
Hu, Xueting ;
Lin, Jiatong ;
Jiang, Ming ;
He, Xiaotian ;
Wang, Kefeng ;
Wang, Wenjian ;
Hu, Chuwen ;
Shen, Zhiwen ;
He, Zhanghai ;
Lin, Huayue ;
Wu, Duoguang ;
Wang, Minghui .
JOURNAL OF CANCER, 2020, 11 (01) :229-240